Actinium Pharmaceuticals to Present Actimab-A Data at the 10th International Symposium on Targeted Alpha Therapy
May 23 2017 - 7:30AM
- Data from the Company’s Actimab-A
program to be presented in the Clinical Experiences session being
held on Wednesday, May 31, 2017
Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the
Company"), a biopharmaceutical Company developing innovative
targeted payload immunotherapeutics for the treatment of advanced
cancers, announced today that data from the Company’s Actimab-A
program will be presented in an oral presentation at the 10th
International Symposium on Targeted Alpha Therapy (TAT10) being
held on May 30 – June 2, 2017 at Kanazawa University in Kanazawa,
Japan. Actinium’s Actimab-A drug candidate is a targeted
radioimmunotherapy that consists of the alpha emitting radioisotope
actinium-225 linked to an anti-CD33 monoclonal antibody. Actimab-A
is currently being studied in a 53-patient, open label, multicenter
Phase 2 clinical trial in patients newly diagnosed with acute
myeloid leukemia (AML) who are age 60 and above.
Dr. Mark Berger, Actinium’s Chief Medical
Officer said, “I very much look forward to presenting data from our
Actimab-A program at the symposium. Given its specific focus on
alpha particle based therapies, I can think of no better venue to
showcase Actimab-A. I am confident that symposium attendees will be
excited to hear about Actimab-A’s potential in acute myeloid
leukemia, where our studies have shown a promising safety and
efficacy profile in this difficult to treat hematologic indication.
The powerful alpha particles enable Actimab-A activity in an
indication where traditional oncology agents have not been able to
produce effective results.”
Additional information about TAT-10 can be found via the
symposium’s
link:http://nucmed.w3.kanazawa-u.ac.jp/symposium/tat10/
Details on Actinium’s oral presentation are
below:
Date: Wednesday, May 31,
2017Session: Clinical
ExperiencesTitle: Efficacy of 225Ac-labeled
anti-CD33 antibody in acute myeloid leukemia (AML) correlates with
peripheral blast count
Actinium’s Executive Chairman Sandesh Seth said,
“Actinium is excited to once again be a sponsor of the
International Symposium on Targeted Alpha Therapy. This conference
has become the leading scientific forum and a key event in the
field of alpha particle based targeted therapies. The symposium
brings together thought leaders in the field from the
pharmaceutical industry, government agencies and academic based
researchers who continue to advance the field and establish alpha
radiation as an effective therapeutic modality. As evidenced by the
quality of the scientific, technological and clinical abstracts,
this year’s symposium is an excellent showcase for the promise that
alpha based therapies hold based on their differentiated biological
profile compared to other forms of radiation and our team is
looking forward to presenting Actimab-A and meeting with symposium
attendees.”
About Actimab-A
Actimab-A, Actinium's most advanced alpha
particle immunotherapy (APIT) product candidate, is currently in a
53-patient, multicenter Phase 2 trial for patients newly diagnosed
with AML age 60 and above. Actimab-A is being developed as a
first-line therapy and is a monotherapy that is administered via
two 15-minute injections that are given 7 days apart. Actimab-A
targets CD33, a protein abundantly expressed on the surface of AML
cells via the monoclonal antibody, HuM195, which carries the potent
cytotoxic radioisotope actinium-225 to the AML cancer calls.
Actinium-225 gives off high-energy alpha particles as it decays,
which kill cancer cells and as actinium-225 decays it produces a
series of daughter atoms, each of which gives off its own alpha
particle, increasing the chances that the cancer cell will be
destroyed. Actimab-A is a second-generation therapy from the
Company’s HuM195-Alpha program, which was developed at Memorial
Sloan Kettering Cancer Center and has now been studied in over 90
patients in four clinical trials. Actimab-A has been granted Orphan
Drug Designation for newly diagnosed AML in patients 60 and above
by the U.S. Food and Drug Administration and the European Medicines
Agency.
About Actinium’s Alpha Particle
Immunotherapy Platform
Actinium's Alpha Particle Immunotherapy (APIT)
platform is a highly potent and selective form of targeted payload
radioimmunotherapy. The APIT platform is based on attaching the
powerful alpha emitting radioisotope Actinium-225 to monoclonal
antibodies (mAbs), which are large molecules capable of binding
specifically to cancer cells. By virtue of carrying alpha emitters,
mAbs bring Actinium-225 directly to cancer cells where alpha
emitters can selectively kill the targeted cell. Actinium-225 emits
significant energy making it a potent against targeted cancer cells
but this energy only travels extremely short distances limiting
damage to healthy tissues. Due to the targeting of this energy by
way of the mAbs bringing the alpha emitting isotopes directly to
cancer cells, Actinium believes Actinium-225 enabled therapies will
result in potentially more effective and at the same time tolerable
therapies.
About Actinium Pharmaceuticals,
Inc.
Actinium Pharmaceuticals, Inc. is a
biopharmaceutical company developing innovative targeted therapies
for patients with cancers lacking effective treatment options.
Actinium's proprietary platform utilizes monoclonal antibodies to
deliver radioisotopes directly to cells of interest in order to
kill those cells safely and effectively. The Company's lead product
candidate Iomab-B is designed to be used, upon approval, in
preparing patients for a hematopoietic stem cell transplant,
commonly referred to as bone marrow transplant. A bone marrow
transplant is often the only potential cure for patients with
blood-borne cancers but the current standard preparation for a
transplant requires chemotherapy and/or total body irradiation that
result in significant toxicities. Actinium believes Iomab-B will
enable a faster and less toxic preparation of patients seeking a
bone marrow transplant, leading to increased transplant success and
survival rates. The Company is currently conducting a single
pivotal 150-patient, multicenter Phase 3 clinical study of Iomab-B
in patients with relapsed or refractory acute myeloid leukemia
(AML) age 55 and older. The Company's second product candidate,
Actimab-A, is currently in a multicenter open-label, 53-patient
Phase 2 trial for patients newly diagnosed with AML age 60 and
over. Actimab-A is being developed to induce remissions in elderly
patients with AML who lack effective treatment options and often
cannot tolerate the toxicities of standard frontline therapies. In
addition, Actinium is developing Actimab-M, which is being studied
in patients with relapsed or refractory multiple myeloma in a Phase
1 clinical trial. Actinium is also utilizing its alpha-particle
immunotherapy (APIT) technology platform to generate new drug
candidates based on antibodies linked to the element Actinium-225
that are directed at various cancers that are blood-borne or form
solid tumors. Actinium Pharmaceuticals is based in New York, NY. To
learn more about Actinium Pharmaceuticals, please visit
www.actiniumpharma.com and to follow @ActiniumPharma on Twitter
please visit, www.twitter.com/actiniumpharma.
Forward-Looking Statements for Actinium
Pharmaceuticals, Inc.
This news release contains "forward-looking
statements" as defined in the Private Securities Litigation Reform
Act of 1995. These statements are based on management's current
expectations and involve risks and uncertainties, which may cause
actual results to differ materially from those set forth in the
statements. The forward-looking statements may include statements
regarding product development, product potential, or financial
performance. No forward-looking statement can be guaranteed and
actual results may differ materially from those projected. Actinium
Pharmaceuticals undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events, or otherwise.
Contact:
Actinium Pharmaceuticals, Inc.
Steve O'Loughlin
Vice President, Finance and Corporate Development
soloughlin@actiniumpharma.com